Poisons and medicine are oftentimes the same substance given with different intents

Peter Mere Latham 1789–1875 English physician & educator

<table>
<thead>
<tr>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>General considerations</td>
</tr>
<tr>
<td>List of adverse effects of TB drugs</td>
</tr>
<tr>
<td>Drug effects on liver</td>
</tr>
<tr>
<td>Drug metabolism by liver</td>
</tr>
<tr>
<td>Spectrum of drug effects on liver</td>
</tr>
<tr>
<td>Commonly used lab tests</td>
</tr>
<tr>
<td>Drug-specific effects on liver</td>
</tr>
<tr>
<td>Monitoring for toxicity</td>
</tr>
<tr>
<td>Management of drug effects on liver</td>
</tr>
<tr>
<td>Management of GI intolerance</td>
</tr>
<tr>
<td>Dermatologic complications</td>
</tr>
<tr>
<td>Neurologic complications</td>
</tr>
<tr>
<td>Includes optic (eye) and otic (ear) ones</td>
</tr>
<tr>
<td>Individual drugs – other side effects</td>
</tr>
</tbody>
</table>

General Considerations
Recognize that treatment is difficult
- Symptoms
  - Drug-related
  - Due to other causes – including TB itself
  - Fear of drugs
- Serious adverse reactions
  - Need to be anticipated
  - May prompt discontinuation / changing medication

Essential elements of a TB program
- Ready access to care for patients
- Adequate education of staff
- Good communication among staff, health care providers, patients
- Standardized approaches
  - Patient education
  - Medical history form
  - Patient instructions
  - # of doses of medications dispensed at a time

Address, relieve symptoms
- Reassure patient
- Emphasize importance of Rx completion
- Be firm: treatment must be completed
- Make it a common goal to complete Rx on time

Make every attempt to avoid unnecessary breaks in therapy
- Remind patient that breaks result in prolonged duration of treatment
Types of Adverse Effects of TB Drugs

Serious Drug Complications
- Hepatotoxicity
- Hearing loss
- Kidney failure
- Vision loss
- Toxic skin / systemic reactions
- Hematologic (blood) reactions
- Electrolyte abnormalities
- Neurologic damage
- Death

Less Serious Complications
- Skin rash, itching
- Nausea, vomiting, diarrhea
- Reversible CNS symptoms
- Bone & joint symptoms
- Endocrine effects (less common)

Effects of Drugs on the Liver
Drug is swallowed
Absorbed from the GI tract into blood vessels
Enters liver via portal vein
Metabolized in liver
One process involves cytochrome P450 class of enzymes
Enters circulation or stored in bile
Bile enters duodenum
Drug is excreted in stool or reabsorbed (Enterohepatic Circulation)

Drug Effects on Liver: A Spectrum
- Fulminant liver disease / death
  - 30% cases in US are caused by drugs
- Drug induced liver injury (DILI)
  - 700 drugs approved in US can cause liver toxicity
  - Important to detect early
- Hepatic adaptation
  - Protective response
- Cholestasis
  - Bile does not flow freely from liver to bowel
  - Asymptomatic elevations in bilirubin

Rifampin Activates
Bile Duct
Portal Vein

Liver cells and bile duct cells contain enzymes
- Involved in metabolism of protein, amino acids
- Released into blood if liver is damaged

ALT (SGPT)
- Released from damaged liver cells into blood
- Most specific test for DILI
- Can be elevated in hepatic adaptation

AST (SGOT)
- Released from damaged liver cells into blood
- Not specific to liver (found in heart, muscle, RBCs)

Lab Tests to Detect Liver Damage

Lab Tests to Detect Bile or Bile Duct Problems
- Alkaline phosphatase
  - Enzyme found in liver cells & cells lining bile ducts
  - Elevated in bile duct obstruction, cholestasis, infiltrative diseases of liver
  - Elevated in children & pregnant women
- GGT
- 5' nucleotidase (5'NTD)
Jaundice

- Bilirubin
  - Results from the breakdown of red blood cells
  - Normally, it passes through the liver, is conjugated (made water soluble), & excreted in stool
  - When the liver cannot handle bilirubin normally or bile flow is impaired, bilirubin leaks into the blood stream
    - Causes jaundice or icterus

Hepatocellular Injury: Hepatic Enzymes ALT & AST

- ALT (SGPT) is more specific for hepatocellular injury than AST (SGOT)
- AST>ALT with alcohol–related disease
  - AST/ALT >2 suggests alcohol is the cause

2.5% of normal, healthy people will have ALT “above upper limit of normal” (ULN)
- Because “normal” levels defined as those within 2 standard deviations of the mean from a healthy population
- It is customary to compare multiples of ULN
  - Interlaboratory variation
  - Variation within an individual up to 45% in a day
- ≥ 3 times ULN with symptoms or ≥ 5 times ULN without symptoms is considered significant

INH

- Cleared in liver by acetylation
- Genetic variation -> fast, slow, & intermediate acetylators
  - Significance unclear
  - Genotyping suggests slow acetylators develop higher peak ALT & more frequent elevations > 3 X ULN than fast acetylators
  - Unknown significance
- Up to 20% people treated with INH alone have low–grade, transient, asymptomatic ALT increase – “hepatic adaptation”
<table>
<thead>
<tr>
<th><strong>INH</strong></th>
<th><strong>Rifampin</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of hepatotoxicity when used alone: 0.1–0.6%</td>
<td>Dose–dependent interference with bilirubin uptake =&gt; subclinical, elevated <em>unconjugated</em> bilirubin &amp; jaundice</td>
</tr>
<tr>
<td>Timing: weeks to months of starting drug</td>
<td>May be transient</td>
</tr>
<tr>
<td>Incidence &amp; severity increases with age</td>
<td>May occur early in treatment</td>
</tr>
<tr>
<td>Risk increases with:</td>
<td>Can also cause asymptomatic elevation</td>
</tr>
<tr>
<td>◦ Chronic alcohol consumption</td>
<td><em>conjugated</em> bilirubin (several mechanisms)</td>
</tr>
<tr>
<td>◦ Active hepatitis B (+HBeAg)</td>
<td></td>
</tr>
<tr>
<td>◦ Elevated baseline transaminases (AST, ALT)</td>
<td></td>
</tr>
<tr>
<td>◦ Concomitant use of other hepatotoxic drugs</td>
<td></td>
</tr>
<tr>
<td>◦ 3rd trimester pregnancy to 3 months post-partum</td>
<td></td>
</tr>
<tr>
<td>◦ Pre-existing liver disease</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Rifampin Hepatotoxicity</strong></th>
<th><strong>Pyrazinamide</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatocellular injury less common</td>
<td>Both dose–dependent &amp; idiosyncratic hepatotoxicity</td>
</tr>
<tr>
<td>◦ Insidious cholestasis</td>
<td>Causes hepatotoxicity less often than INH <em>but</em></td>
</tr>
<tr>
<td>◦ Anorexia, nausea, vomiting, fever, jaundice</td>
<td>◦ Can be more prolonged</td>
</tr>
<tr>
<td>◦ Mildly elevated ALT, elevated bilirubin</td>
<td>◦ Can continue after drug discontinued</td>
</tr>
<tr>
<td>◦ Usually occurs in first month of treatment</td>
<td>◦ Can be most severe</td>
</tr>
<tr>
<td>◦ RIF is much less likely to cause hepatotoxicity than INH or PZA</td>
<td>Can cause granulomatous hepatitis</td>
</tr>
<tr>
<td></td>
<td>◦ Fever, rash, lymphadenopathy, elevated ALT</td>
</tr>
</tbody>
</table>
**Assess risk before treatment**

Baseline blood tests NOT generally recommended for healthy patients treated with INH or RIF alone.

Face-to-face clinical assessments are cornerstone of monitoring.

Obtain ALT & bilirubin at baseline & q 2-4 weeks for those with risk factors.

- Use ULN for ALT.

ALT is preferred marker for hepatotoxicity in those with symptoms.

**Hepatotoxicity: Special Considerations**

- If baseline ALT > 3 times ULN screen for cause, assess risk for LTBI vs. risk for liver disease.

- Test for HBeAg if ALT is elevated in those who are Hepatitis B surface antigen-seropositive.
  - If HBeAg is +,
    - Rifampin may be preferred.
    - Consider referral for possible pre-treatment of Hepatitis B if ALT > 2 times ULN.
    - Monitor every 2-4 weeks clinically & with ALT.

**Management of Hepatotoxicity: LTBI**

- Stop hepatotoxic drugs immediately for persistent nausea, vomiting, abdominal pain, unexplained fatigue. Contact physician.

- Measure ALT, bilirubin ASAP.

- For intermittent, transient symptoms administer drugs with food, reassure patient.

- Withhold INH if ALT ≥ 3 times ULN if symptoms are present OR ≥ 5 times ULN without symptoms.

- Rechallenge.
  - If it is unclear that INH was the cause.
  - INH was withheld before threshold was reached.

**Monitoring for & Managing Hepatotoxicity: Tuberculosis**

- Obtain baseline ALT, AST, bilirubin, alkaline phosphatase, creatinine, platelet count on all adults.

- Periodic monitoring for those with risk factors.

- Drugs should not be discontinued for mild GI complaints.

- Stop all hepatotoxic drugs if ALT ≥ 3 times ULN with symptoms OR ≥ 5 times ULN without symptoms.

- Substitute non-hepatotoxic drugs.

- When ALT < 2 times ULN, reintroduce rifampin.

- After 3-7 days, reintroduce INH.

- Consider reintroducing PZA only if hepatotoxicity was not severe.
**GI Upset**

- Improves if drugs are administered with food or closer to bedtime
- Ethionamide
  - Causes profound GI symptoms
  - Metallic taste, nausea, vomiting that can be severe, loss of appetite, abdominal pain
  - Dose-related
  - May give as split dose
- P-Aminosalicylic Acid (PAS)
  - Significant GI intolerance, less with granular formulation
  - Dose-related
- INH
  - Commercial liquid preparations contain sorbitol which can cause diarrhea

**Skin Toxicity**

**Dermatologic Reactions**

- Itching with or without erythematous rash is common early side effect
  - May resolve after 1st several weeks of therapy without stopping medications
  - For mild or localized reaction, continue treatment & treat the rash and pruritis symptomatically - antihistamines, topical steroids
- Photosensitivity
  - PZA, fluoroquinolones

**Hydroxyzine (Atarax®, Vistaril®)**

- Indications
  - Itching: 25–100 mg every 6–8 hours
  - Nausea, vomiting: 25–100 mg every 4–6 hours (IM or PO)
  - Anxiety: 50–100 mg every 6 hours
  - Insomnia: 50–100 mg
- Maximum daily dose: 600 mg
Dermatologic Reactions

- Hives, urticaria, erythematous rash
  - Any drug
  - Stop all drugs immediately, re-challenge 1 at a time
  - Wait for rash to resolve
  - Start RIF 1st (least likely to be cause)
  - If no recurrence after 2-3 days, start INH
  - Continue with EMB or PZA
  - Discontinue any drug which causes recurrence
- Angioedema, anaphylaxis, or airway compromise
  - Stop drug – consider desensitization in ICU

Other Serious Dermatologic Reactions

- Spectrum of diseases – generalized, involve mucus membranes, cause fever – epidermis separates from dermis
  - Stevens-Johnson Syndrome
  - Toxic Epidermal Necrolysis (severe form SJS)
- Mortality high
- Quinolones
- Emergency, hospitalization
- Stop offending drug, do not use again

Neurotoxicity

- Numbness, tingling hands & feet in stocking-glove pattern

- Risk factors: diabetes, alcoholism, HIV, hypothyroidism, pregnancy, poor nutrition, inadequate dietary intake of pyridoxine

- Pyridoxine supplements
  - 10–50 mg daily (should this be routine?) for INH
  - 100–200 for cycloserine &/or ethionamide
**Peripheral Neuropathy**

- **INH**
  - Dose-related
  - Interferes with biologic function of vitamin B6
- **Ethionamide**
  - Increased incidence with prolonged use
- **Linezolid**
  - Increased incidence with prolonged use
  - 600 mg daily instead of twice daily is used to prevent this
- **Ethambutol, cycloserine**
  - Rare

**CNS Effects**

- **INH**
  - Inability to concentrate, irritability, dysarthria, seizures, dysphoria
- **Cycloserine (my mnemonic – cyclo, psycho)**
  - Headache, restlessness, psychosis, seizures (dose-related)
  - Pyridoxine 100-200 mg daily to prevent / treat
- **Ethionamide**
  - Anxiety, depression, psychosis
  - Increased incidence with prolonged treatment
- **Fluoroquinolones**
  - Dizziness, insomnia, tremulousness, headache

**Vision – E – E Eye**

- **Ethambutol**
  - Retrobulbar neuritis
  - Dose related – very rare (if at all) with currently recommended doses
  - Decreased red-green color discrimination (1 or both eyes), decreased visual acuity
  - ↑ With renal disease
- **Ethionamide**
  - Optic neuritis
  - Dose related

**Ototoxicity: 8th Cranial Nerve Damage**

- **Streptomycin (SM)**
  - Vestibular (balance) and hearing disturbance
  - Related to single dose size and cumulative dose (>100-200 g)
  - Increased incidence if diuretics are used
  - Monitor with audiogram, Romberg
  - Hearing loss can be permanent – consider stopping
- **Amikacin & Kanamycin**
  - Less vestibular toxicity than SM
- **Capreomycin**

These drugs also cause nephrotoxicity & require monitoring
Injectable agents – 15mg/kg daily or 25 mg/kg TIW
- Ototoxicity often permanent
  * Hearing loss ≥ 20 dB occurred in 32/87 (37%) patients, 88% had persistent loss at end of follow-up
  * Associated with older age, duration of treatment, & total dose
  * Not associated with vestibular or renal toxicity
  * Amikacin > Kanamycin > Streptomycin
- TIW = daily Rx


Flu-like syndrome with fever, chills, headache, & bone pain
  - Can begin 1-2 hrs after medication dose and resolve spontaneously after 6-8 hrs
  - More common in intermittent dosing, higher dose
  - Can try daily therapy if mild

Severe immunologic reactions – rare, each < 0.1% patients
  - Low platelet count / petechiae
  - Kidney dysfunction
  - Hemolytic anemia
  - Thrombotic thrombocytopenic purpura
Rifampin

- Red–orange discoloration urine, tears, perspiration, feces
  - Can permanently discolor soft contact lenses

Pyrazinamide (PZA)

- Arthralgias common – Rx symptomatically
- Elevated uric acid
  - PZA is a pro-drug, converted to the active compound Pyrazinoic acid
  - Pyrazinoic acid blocks renal tubular excretion of uric acid => elevated uric acid
  - Allopurinol does not reverse this
  - Routine measurement of uric acid is not recommended
  - Gout is rare
  - Hyperuricemia without gout is not a reason for discontinuing drug

Ethionamide

- Endocrine disturbances
  - Gynecomastia, alopecia, hypothyroidism, impotence
  - Diabetes may be more difficult to manage
  - Acne
  - Irregular menstrual cycles

Capreomycin

- Electrolyte disturbances
  - Potassium, calcium, and magnesium depletion
- Proteinuria is common
Quinolones

- Tendonitis, tendon rupture – very rare
  - All ages
  - Greater risk age >60
  - Patients taking corticosteroids
  - Transplant patients
- QTc prolongation
- Nausea & diarrhea

PAS

- Hypothyroidism is common
  - Increased incidence when used with ethionamide
  - Reversible when drug stopped
  - Goiter can develop
- Malabsorption
  - Steatorrhea (fat malabsorption)
  - Doubling of prothrombin time
    - Vitamin K is a fat soluble vitamin
  - Levels of fat soluble vitamins (A, D, E) can be measured & monitored

Linezolid

- Myelosuppression
- Serotonin syndrome
- Nausea & diarrhea

Stuff Happens; Be Prepared